Skye Bioscience (SKYE) Total Non-Current Liabilities (2014 - 2022)
Skye Bioscience (SKYE) posted quarterly Total Non-Current Liabilities of $6.2 million for Q3 2022, up 91.43% year-over-year from $3.2 million in Q3 2021, and up 16.93% quarter-over-quarter from $5.3 million in Q2 2022.
Skye Bioscience (SKYE) Total Non-Current Liabilities (2014 - 2022) Analysis & Trends
Skye Bioscience (SKYE) has reported Total Non-Current Liabilities for 9 consecutive years, with $6.2 million the latest figure, recorded in Q3 2022.
- In Q3 2022, Total Non-Current Liabilities rose 91.43% year-over-year to $6.2 million; the TTM figure through Sep 2022 stood at $6.2 million (up 91.43% YoY), while the FY2021 annual figure was $3.9 million, up 80.13% from the prior year.
- Total Non-Current Liabilities grew to $6.2 million in Q3 2022 per SKYE's latest filing, from $5.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $31.6 million in Q1 2019 and bottomed at $195771.0 in Q2 2018.
- Historically, Total Non-Current Liabilities has averaged $5.5 million across 5 years, with a median of $3.2 million in 2021.
- Annual changes were most pronounced in 2018 — Total Non-Current Liabilities soared 3037.9% — and 2019, when it slumped 94.52%.
- Skye Bioscience's Total Non-Current Liabilities stood at $17.3 million in 2018, then plunged by 94.52% to $947285.0 in 2019, then surged by 130.38% to $2.2 million in 2020, then jumped by 80.13% to $3.9 million in 2021, then jumped by 56.53% to $6.2 million in 2022.
- Business Quant data shows SKYE's Total Non-Current Liabilities at $6.2 million in Q3 2022, $5.3 million in Q2 2022, and $4.2 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.32 Bn |
| 10 | Skye Bioscience | 10.72 Mn | 10.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 6.15 Mn |
| Jun 30, 2022 | 5.26 Mn |
| Mar 31, 2022 | 4.22 Mn |
| Dec 31, 2021 | 3.93 Mn |
| Sep 30, 2021 | 3.21 Mn |
| Jun 30, 2021 | 2.82 Mn |
| Mar 31, 2021 | 2.64 Mn |
| Dec 31, 2020 | 2.18 Mn |
| Sep 30, 2020 | 2.46 Mn |
| Jun 30, 2020 | 2.86 Mn |
| Mar 31, 2020 | 1.94 Mn |
| Dec 31, 2019 | 947,285.00 |
| Sep 30, 2019 | 3.82 Mn |
| Jun 30, 2019 | 3.54 Mn |
| Mar 31, 2019 | 31.63 Mn |
| Dec 31, 2018 | 17.30 Mn |
| Sep 30, 2018 | 210,434.00 |
| Jun 30, 2018 | 195,771.00 |
| Mar 31, 2018 | 8.59 Mn |
| Dec 31, 2017 | 551,322.00 |